
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
`
+3
Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds for in-licensing, we conduct clinical development and then select large pharmaceutical commercialization partners for out-licensing to maximize patient access across the globe. Through this specialized business model, Debiopharm can focus on the development of prescription drugs that target unmet medical needs in oncology and bacterial infections. Debiopharm completed the development and has licensed out 2 compounds: - Triptorelin, the active substance of Decapeptyl/Trelstar/Pamorelin/Triptodur 1, 3 and 6-month formulation and Moapar/Salcacyl -Oxaliplatin, the active substance of the branded Eloxatin/Elplat/Dacotin/Dacplat If your university or biotech start-up has...
Drug development,digital health,oncology,antimicrobials,healthcare,biopharmaceutical,drug delivery,and science and innovation
Debiopharm operates in the Pharmaceutical manufacturing industry.
Debiopharm's revenue is 11m - 100m
Debiopharm has 501 - 1000 employees.
Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.
Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.
Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.